Interindividual variations in metoprolol metabolism--some clinical and other observations.
作者信息
Regårdh C G, Johnsson G
出版信息
Br J Clin Pharmacol. 1984 Apr;17(4):495-6. doi: 10.1111/j.1365-2125.1984.tb02381.x.
Abstract
摘要
相似文献
1
Interindividual variations in metoprolol metabolism--some clinical and other observations.美托洛尔代谢的个体间差异——一些临床及其他观察结果。
Br J Clin Pharmacol. 1984 Apr;17(4):495-6. doi: 10.1111/j.1365-2125.1984.tb02381.x.
2
Lack of evidence for polymorphism in metoprolol metabolism.美托洛尔代谢中缺乏多态性的证据。
Br J Clin Pharmacol. 1983 Aug;16(2):188-90. doi: 10.1111/j.1365-2125.1983.tb04984.x.
3
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中，美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
4
Pregnancy-induced increase in metoprolol metabolism.妊娠引起的美托洛尔代谢增加。
Clin Pharmacol Ther. 1985 Jun;37(6):688-92. doi: 10.1038/clpt.1985.114.
5
Biotransformation of metoprolol by the fungus Cunninghamella blakesleeana.布氏被孢霉对美托洛尔的生物转化
Acta Pharmacol Sin. 2007 Jul;28(7):1067-74. doi: 10.1111/j.1745-7254.2007.00567.x.
6
Effects of ranitidine on the disposition of metoprolol.雷尼替丁对美托洛尔处置的影响。
Br J Clin Pharmacol. 1985 Feb;19(2):219-24. doi: 10.1111/j.1365-2125.1985.tb02634.x.
7
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
8
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.美托洛尔在异喹胍代谢快者和慢者中的差异立体选择性代谢。
Clin Pharmacol Ther. 1983 Dec;34(6):732-7. doi: 10.1038/clpt.1983.242.
9
Metabolism of metoprolol in the rat in vitro and in vivo.美托洛尔在大鼠体内外的代谢
Xenobiotica. 1976 Nov;6(11):691-711. doi: 10.3109/00498257609151681.
引用本文的文献
1
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.多态性药物氧化：药代动力学基础及实验指标比较
Br J Clin Pharmacol. 1986 Nov;22(5):541-50. doi: 10.1111/j.1365-2125.1986.tb02933.x.
2
Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.美托洛尔。对其药效学和药代动力学特性以及在高血压、缺血性心脏病和相关心血管疾病中的治疗效果的最新综述。
Drugs. 1986 May;31(5):376-429. doi: 10.2165/00003495-198631050-00002.
3
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
4
Oxidation phenotype and the metabolism and action of beta-blockers.
Klin Wochenschr. 1985 Apr 1;63(7):285-92. doi: 10.1007/BF01731972.
5
Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.在健康受试者中，异喹胍氧化表型对美托洛尔和阿替洛尔治疗后的运动耐量和主观疲劳的影响。
Br J Clin Pharmacol. 1991 Apr;31(4):391-8. doi: 10.1111/j.1365-2125.1991.tb05551.x.
本文引用的文献
1
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
2
3
Lack of evidence for polymorphism in metoprolol metabolism.美托洛尔代谢中缺乏多态性的证据。
Br J Clin Pharmacol. 1983 Aug;16(2):188-90. doi: 10.1111/j.1365-2125.1983.tb04984.x.
4
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中，美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
5
Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris.五种具有不同辅助特性的β-肾上腺素能受体阻滞剂对心绞痛即时疗效的比较。
N Engl J Med. 1979 Apr 5;300(14):750-5. doi: 10.1056/NEJM197904053001402.
6
Once daily administration of sustained release propranolol capsules in the treatment of angina pectoris.缓释普萘洛尔胶囊每日一次给药治疗心绞痛。
Eur J Clin Pharmacol. 1979;16(6):387-91. doi: 10.1007/BF00568198.
Zotero 插件